• July 8, 2022

    On July 7, 2022, the Bulgarian Credit Rating Agency (BCRA) has awarded the company with the highest market capitalization on the Bulgarian Stock Exchange Tchaikapharma a long-term credit rating of “BBB-” and a short-term “A” on a national scale. With this, BCRA expresses its opinion that the company maintains a very good financial position with […]

  • July 4, 2022

    “Politicians in power have one main task – to create a competitive investment and business environment and deal with the growth of the national economy. The self-esteem of any nation is a product of GDP per capita. Politicians should focus on this issue.” This is what Tihomir Kamenov, a specialist in public and private law, […]

  • June 13, 2022

    Tchaikapharma has expanded its portfolio with another product, namely Fluidoro 10 mg film-coated tablets (with active ingredient prasugrel). It belongs to a group of drugs called platelet antiaggregants – it inhibits the accumulation of platelets and thus reduces the risk of blood clots.   Fluidoro, given concomitantly with acetylsalicylic acid (ASA), is indicated for the […]

  • May 20, 2022

    Tchaikapharma’s product portfolio was presented at the 6th congress of the Society of Cardiologists of Kosovo under the auspices of the European Society of Cardiology. Тhe company’s top products Tamaira, Co-Telsart, Amariton and Rosta were of particular interest as the preferred choice of the cardiologists in the country. This is one of the reasons why […]

  • April 4, 2022

    The pandemic has caused problems in the forefront of predictability and access to medicines in the country. It was difficult to supply the basic (active) substances for pharmaceutical production, and a slight increase in the production of drugs.   In this context, even before the first global lockdown, the team of Tchaikapharma has prepared a […]